Nevro (NVRO) to Release Earnings on Wednesday

Nevro (NYSE:NVRO - Get Free Report) is anticipated to release its earnings data before the market opens on Wednesday, February 19th. Analysts expect Nevro to post earnings of ($0.67) per share and revenue of $102.43 million for the quarter.

Nevro Trading Down 0.1 %

NVRO traded down $0.01 on Friday, hitting $5.72. The company had a trading volume of 890,192 shares, compared to its average volume of 1,156,006. The company has a market cap of $214.14 million, a PE ratio of -3.02 and a beta of 0.91. Nevro has a 12-month low of $3.16 and a 12-month high of $17.63. The company has a quick ratio of 3.76, a current ratio of 5.02 and a debt-to-equity ratio of 0.67. The business's fifty day simple moving average is $4.45 and its 200 day simple moving average is $5.04.

Wall Street Analyst Weigh In

Several research analysts recently commented on the company. Robert W. Baird lifted their price target on Nevro from $5.00 to $6.00 and gave the stock a "neutral" rating in a research report on Tuesday, November 12th. JMP Securities restated a "market perform" rating on shares of Nevro in a research report on Tuesday, November 12th. Jefferies Financial Group upgraded Nevro from an "underperform" rating to a "hold" rating and boosted their target price for the company from $4.50 to $5.85 in a research report on Monday, February 10th. Royal Bank of Canada restated a "sector perform" rating and set a $7.00 target price on shares of Nevro in a research report on Tuesday, November 12th. Finally, Piper Sandler upgraded Nevro from a "neutral" rating to an "overweight" rating and dropped their target price for the company from $6.00 to $5.85 in a research report on Friday, February 7th. Two research analysts have rated the stock with a sell rating, twelve have given a hold rating and one has issued a buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Hold" and an average price target of $6.43.

Nevro Company Profile

Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems.